Rhythm Pharmaceuticals, Inc. (RYTM)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 3 | 24 | 77 | 130 | 190 | 240 | 317 |
| Operating profit | $m | -192 | -201 | ||||||
| Net profit | $m | -131 | -70 | -181 | -185 | -261 | -197 | -205 | -210 |
| EPS reported | $ | -3.11 | -3.11 | ||||||
| Operating cashflow per share | $ | -1.78 | -2.18 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | -1.79 | -2.19 | ||||||
| Free cash flow | $m | -117 | -150 | ||||||
| Net debt | $m | -389 | -331 | ||||||
| Book value equity | $m | 270 | 217 | ||||||
| Book value per share | $ | 4.16 | 3.17 | ||||||
| Number of shares | m | 64.98 | 68.59 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 25.76 | 32.01 | ||||||
| P/S LTM | x | 36.66 | 28.99 | ||||||
| P/FCF LTM | x | -59.64 | -46.22 | ||||||
| EV/EBITDA LTM | x | -39.66 | -37.38 | ||||||
| EV/Sales LTM | x | 36.39 | 32.76 | ||||||
| Earnings Yield LTM | % | -2.83% | -2.59% | ||||||
| FCF Yield | % | -1.68% | -2.16% | ||||||
| Quality | |||||||||
| ROE | % | -72.79% | -80.48% | ||||||
| ROIC | % | -51.22% | -63.82% | ||||||
| Operating margin | % | -1.01% | -83.62% | ||||||
| Gross margin | % | +89.73% | +89.00% | ||||||
| FCF/Sales | % | -61.46% | -62.72% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +45.83% | +84.37% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | -100.00% | -100.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -29.22 | -40.87 | ||||||
| Net Debt/EBITDA | x | 0.29 | 0.34 | ||||||
| EBIT/Net interest | x | -9.33 | -10.86 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -1.44 | -1.52 | ||||||
| Gross debt/equity | x | 0.01 | 0.02 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Rhythm Pharmaceuticals, Inc. (RYTM)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free